Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion
about
Maresin 1 induces a novel pro-resolving phenotype in human plateletsReal-Time Live Confocal Fluorescence Microscopy as a New Tool for Assessing Platelet Vitality.15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes.Reactions Induced by Platelet Transfusions.Platelet transfusion alters CD40L blood level and release capacity in patients suffering from thrombocytopenia.Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitroA computerized prediction model of hazardous inflammatory platelet transfusion outcomes.The platelet as an immune cell-CD40 ligand and transfusion immunomodulationPlatelet proteome changes associated with diabetes and during platelet storage for transfusion.Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes.Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products.Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system.Transfusion immunomodulation--the case for leukoreduced and (perhaps) washed transfusions.The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.Resveratrol preserves the function of human platelets stored for transfusion.The pro-inflammatory effects of platelet contamination in plasma and mitigation strategies for avoidance.CD40 ligand (CD154) involvement in platelet transfusion reactions.Hemostatic function of apheresis platelets stored at 4°C and 22°C.Platelet storage and transfusions: new concerns associated with an old therapy.A comparison of adverse reaction rates for PAS C versus plasma platelet units.Platelet transfusion - the new immunology of an old therapy.Transfusion-related acute lung injury: transfusion, platelets and biological response modifiers.Increased risk of cardiovascular disease in premenopausal female ragpickers of Eastern India: involvement of inflammation, oxidative stress, and platelet hyperactivity.In Vitro and Ex Vivo Approaches to Evaluate Next-Generation Tobacco and Non-Tobacco Products on Human Blood Platelets.Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates.Statin islands and PPAR ligands in platelets.Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40-CD40L system as a potential target.Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions.Response: Are PDMVs the biologically active source of CD154 in ATR?Prolonged platelet storage associated with increased frequency of transfusion-related adverse events.Modeling the effect of platelet concentrate supernatants on endothelial cells: focus on endocan/ESM-1.Leucocyte cytokines dominate platelet cytokines overtime in non-leucoreduced platelet components.Increased complement activation during platelet storage.Removal of biological response modifiers associated with platelet transfusion reactions by columns containing adsorption beads.Platelet-derived microparticles induce polymorphonuclear leukocyte-mediated damage of human pulmonary microvascular endothelial cells.Storage of aliquots of apheresis platelets for neonatal use in syringes with and without agitation.The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro
P2860
Q29248094-C278DD41-2CDD-4D30-B42A-F3E3A9EEEF29Q30497360-3F7A36FC-950F-4489-9262-1666D79E87C8Q33380951-E518E9B9-ED95-4FC4-9A18-C304310F1D77Q33395008-A86DEF49-97C4-4788-BBBF-15463EE858B7Q33398221-722FAB96-8430-4B97-BD58-4659AC959D14Q33568350-E9ECFA4A-B790-4E57-AF8D-C8C70891FCBCQ33618448-84290D0A-F34B-4324-B694-86276AF11DD1Q33937074-C9833F68-9CD2-43B3-BDA2-AB2155CD9C2AQ34474697-A24DD3BD-A0F6-4EB8-8B25-D8A44D845799Q34708937-84554F8B-BEA3-4BC9-9181-CC08317B3164Q35924467-73E7F4EF-30F1-4E69-BD21-51D1B6EAF887Q36393452-3F1A14B1-B906-4DBD-87C4-4BA29BE9ED70Q36428284-3B175901-DA14-4188-8DC3-B3975BFCCD9EQ36445381-BDE451CC-436B-4588-BCE0-903B45B6D2DEQ36609428-9691A41E-7888-4A70-BE1F-A8F0CCFC12AAQ36950012-3775F50A-592D-4579-A3C9-91C5D640056EQ37429101-7186091A-F01C-4DBC-AFCF-9195DB193F3FQ37710229-8612993E-E8AC-48A1-995C-4B0A755B5191Q38015853-65E8626F-5F64-43C8-BDCF-AFD95DBAD831Q38204784-C845D447-6FC2-40EF-AD89-B8C9C5FD3A0DQ38362628-BE7ED0BA-9804-43EA-8932-B1B22857AB07Q38725992-7CD62CB1-32D5-4673-82B9-A9D5543B34B6Q40649053-A30EC0EF-B9F2-46AC-80F4-BC51596EB885Q41831369-46B9264D-D079-40BC-9A96-0645D62884DCQ41965815-DB9859BC-3BCB-42B4-B749-618D1697F1FEQ42557418-E4E36B3F-5E32-424D-9419-F3A889D2434BQ42740250-A0606EB9-F7C4-4915-BE17-70C3B8610A63Q45832206-52172B50-F3F5-43FB-BF0B-29A67D659B40Q45832958-ACA1346E-272E-4C0D-86F7-78767B1D7F8BQ48112813-BF869B1D-6644-46A4-AAD5-FAA0705F121FQ48120435-A2E24A8B-92BA-4FE2-B798-5309A1CAD893Q49443114-9E789A84-08C9-44A1-9A85-1831EE4AFAA0Q50248278-BDD73BFB-8EAF-48B2-9939-628235081206Q50481057-D177D3E5-53C1-4200-B15E-AF053322E670Q51669619-0C651AE8-AEEF-48A2-9F84-808FB5687941Q53234203-4ABC502B-9974-49A0-8F57-AE83F2E40732Q57166290-DC334A59-F29D-4B30-B9DF-023CC7615266
P2860
Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Release of biologically active ...... rates prepared for transfusion
@ast
Release of biologically active ...... rates prepared for transfusion
@en
Release of biologically active ...... rates prepared for transfusion
@nl
type
label
Release of biologically active ...... rates prepared for transfusion
@ast
Release of biologically active ...... rates prepared for transfusion
@en
Release of biologically active ...... rates prepared for transfusion
@nl
prefLabel
Release of biologically active ...... rates prepared for transfusion
@ast
Release of biologically active ...... rates prepared for transfusion
@en
Release of biologically active ...... rates prepared for transfusion
@nl
P2093
P2860
P1476
Release of biologically active ...... rates prepared for transfusion
@en
P2093
N Blumberg
R P Phipps
S L Spinelli
P2860
P304
P356
10.1111/J.1538-7836.2007.02412.X
P407
P577
2007-04-01T00:00:00Z